Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)

第2相 完了 NCT06482112

概要

This study will evaluate the effect of efinopegdutide administration once every 2 weeks (Q2W) versus once weekly (Q1W) on mean relative reduction from baseline in liver fat content (LFC) after 28 weeks, as well as the safety and tolerability of the different regimens of efinopegdutide.

Mean Relative Reduction From Baseline in Liver Fat Content at Week 28

Baseline and Week 28 · Percent Reduction

Percentage of Participants Who Experienced an Adverse Event (AE)

Up to Week 32 · Percentage of participants

Percentage of Participants Who Discontinued Study Intervention Due to an AE

Up to Week 28 · Percentage of participants

BENITIONS で見る ClinicalTrials.gov の原文を見る

同じ疾患の他の治験

• A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatoh — Akero Therapeutics, Inc
• Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Va — Galectin Therapeutics Inc.
• Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease — Wake Forest University Health Sciences
• Effect of Obesity on Proton Pump Inhibitors — Children's Mercy Hospital Kansas City
• Phase 2a Study of HPG1860 in Subjects With NASH — Hepagene (Shanghai) Co., Ltd.
• Vitamin E Dosing Study — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

すべての治験